Palo Alto Investors LLC increased its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 6.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,406,475 shares of the company’s stock after buying an additional 206,079 shares during the period. Karyopharm Therapeutics comprises 2.1% of Palo Alto Investors LLC’s holdings, making the stock its 16th largest position. Palo Alto Investors LLC owned about 7.23% of Karyopharm Therapeutics worth $43,739,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in KPTI. Metropolitan Life Insurance Co. NY increased its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock worth $206,000 after buying an additional 2,460 shares during the period. Trexquant Investment LP bought a new position in shares of Karyopharm Therapeutics during the fourth quarter worth about $273,000. State Street Corp increased its position in shares of Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock worth $3,820,000 after buying an additional 25,015 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock worth $2,454,000 after buying an additional 202,714 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in shares of Karyopharm Therapeutics during the fourth quarter worth about $343,000. Institutional investors own 57.11% of the company’s stock.
Karyopharm Therapeutics Inc. (NASDAQ KPTI) traded up 1.53% on Tuesday, reaching $9.32. The company’s stock had a trading volume of 200,553 shares. The firm has a 50-day moving average of $9.18 and a 200 day moving average of $10.19. Karyopharm Therapeutics Inc. has a 12-month low of $6.27 and a 12-month high of $14.63. The company’s market capitalization is $439.14 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.04. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.02 million. Karyopharm Therapeutics had a negative return on equity of 72.41% and a negative net margin of 50,646.40%. During the same period in the prior year, the firm earned ($0.75) earnings per share. On average, equities research analysts anticipate that Karyopharm Therapeutics Inc. will post ($2.68) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/06/20/palo-alto-investors-llc-buys-206079-shares-of-karyopharm-therapeutics-inc-kpti.html.
A number of research analysts recently issued reports on KPTI shares. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective (down from $15.00) on shares of Karyopharm Therapeutics in a research note on Tuesday, March 7th. Canaccord Genuity reiterated a “buy” rating and set a $20.00 price objective on shares of Karyopharm Therapeutics in a research note on Monday, March 13th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 21st. Wedbush reiterated an “outperform” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Saturday, March 4th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, April 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Karyopharm Therapeutics has an average rating of “Buy” and an average target price of $14.46.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.